Progress in adjuvant treatment of melanoma patients

Abstract

Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.